Sphingolipids (SLs) are ubiquitous cell membrane components that regulate multiple cellular processes, such as cell division, differentiation, apoptosis and autophagy[@b1][@b2]. The metabolism of SL is a complex pathway that generates sphingosine-1-phosphate (S1P) from various precursors, using ceramide as a backbone. Ceramide is produced from either *de novo* SL synthesis or sphingomyelin (SM)[@b3]. Ceramide is deacetylated by ceramidases to produce sphingosine, which is then phosphorylated by sphingosine kinase types 1 and 2, producing S1P[@b3].

The potential roles of SL metabolites in respiratory diseases have been discussed, although there is some debate[@b4][@b5]. Acid sphingomyelinase, an enzyme of SM hydrolysis, is involved in endothelial dysfunction, cytokine responses and neutrophils sequestration during acute lung injury[@b5]. Decreased serine palmitoyl-CoA transferase (SPT) activity is associated with methacholine-induced airway hyperreactivity[@b6]. Ceramide expression has been detected in patients with emphysema and chronic-obstructive pulmonary disease[@b7].

Previous studies linking asthma to SL have focused on airway inflammation and allergic responses related to S1P. S1P can initiate mast cell activation and chemotaxis as well as amplify mast cell degranulation by interacting with S1P receptors, primarily S1P~1~ and S1P~2~[@b8][@b9]. An *in vivo* study has reported that S1P treatment induced secretion of T-helper 2 lymphocyte (Th2) and Th17 cytokines, such as interleukin-4 (IL-4) and IL-17, respectively[@b10]. S1P has also been associated with methacholine-induced airway hyperreactivity, bronchoconstriction and airway remodeling by targeting genes regulating cell proliferation[@b4][@b11][@b12].

Asthma is a common and clinically heterogeneous disorder that is characterized by intermittent airflow obstruction, airway hyperreactivity, chronic airway inflammation, and increased mucus production[@b13]. Because of its heterogeneity, asthma is hard to explain by a single mechanism. Lotvall *et al*. have introduced the definition "endotype" to define different asthma subtypes, based on their mechanisms[@b14]. Asthma could be classified into six endotypes (depending on the disease characteristics), including aspirin-exacerbated respiratory disease (AERD) and aspirin-tolerant asthma (ATA). AERD, also termed "aspirin sensitive asthma", is a syndrome triggered by ingesting non-steroidal anti-inflammatory drugs (NSAIDs) that is associated with an increased production of cysteinyl leukotrienes (CysLTs). AERD is likely to be a more severe case of asthma, with a higher frequency of emergency visits/hospitalizations and increased mortality versus allergic asthma[@b15][@b16][@b17]. However, we still lack good biomarkers to differentiate AERD from ATA.

Given that SLs, particularly S1P, could contribute to the pathogenesis of airway inflammation and asthma, we aimed to investigate the SL profiles of AERD patients and its association with clinical outcomes. The serum and urine samples from AERD and ATA patients were analyzed for SL metabolites using lipid chromatograpy- mass spectrometry. Additionally, we searched for a correlation between SL metabolites and key AERD biomarkers, 15-hydroxyeicosatetraenoic acid (15-HETE)[@b18], human leukocyte antigen *HLA-DBP1\*0301*[@b19], cysteinyl leukotriene receptor type 1 (*CYSLTR1)* gene polymorphism[@b20] and periostin[@b21]. To discriminate AERD from ATA, receiver operating characteristics (ROC) curve analysis for serum S1P and urine sphingosine were analyzed.

Results
=======

Patient characteristics
-----------------------

[Table 1](#t1){ref-type="table"} shows the clinical characteristics of the study subjects. The AERD patients showed a greater decrease in FEV~1~ (%) following the Lysine-Aspirin bronchoprovocation test (ASA-BPT) than the ATA patients (*P* \< 0.001). The AERD patients were younger than the ATA patients (*P* = 0.045). The AERD patients showed a larger decline in FEV~1~ (%) predicted values following the ASA-BPT and a lower PC~20~ value than the ATA patients (*P* \< 0.001 and *P* = 0.004, respectively). The AERD patients had higher frequencies of rhinosinusitis and nasal polyposis compared with the ATA patients (86.7% vs. 61.9%, *P* = 0.013 and 37.8% vs 16.7%, *P* = 0.033, respectively). There were no significant differences between the AERD and ATA patients in terms of the other baseline characteristics.

Correlation of the serum SM levels with methacholine-induced airway hyperreactivity
-----------------------------------------------------------------------------------

The serum and urine SL compositions for the AERD and ATA patients during the ASA-BPT are provided in [Table 2](#t2){ref-type="table"}. To determine how SL metabolites changed following the ASA-BPT, we used star and symbol plotting to consider the induction fold of SL metabolites following the ASA-BPT in the AERD and ATA groups (Fig. E1). The SL profiles of the AERD group showed distinct patterns compared with those of the ATA group. Distorted increased patterns of ceramides and SMs after the ASA-BPT were characteristic for the ATA group, while decreased patterns of ceramides and SMs were observed in the AERD group following the ASA-BPT.

Comparing changes in the SL metabolite levels during the ASA-BPT, the levels of serum SMs (d18:0/18:0, d18:0/18:1, d18:0/24:0, d18:0/24:1) were significantly decreased during the follow-up after exposure to ASA through the ASA-BPT in the AERD group (*P* \< 0.05 for each, [Fig. 1a](#f1){ref-type="fig"}, [Table 2](#t2){ref-type="table"}), but not in the ATA group (*P* \> 0.05 for each, [Table 2](#t2){ref-type="table"}). The levels of serum SMs (d18:0/16:0, d18:0/18:1, d18:0/24:0, Lyso SM) showed positive correlations with methacholine-induced airway hyperreactivity (*P* = 0.051, *P* = 0.067, *P* = 0.033, *P* = 0.014, *P* = 0.071, *P* = 0.050 for each, [Fig. 1b](#f1){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). Regarding S1P, the levels in serum and urine samples were increased significantly following the ASA-BPT in both AERD and ATA groups (*P* \< 0.05 for each, [Table 2](#t2){ref-type="table"}).

Serum S1P and urine sphingosine as potential biomarkers to differentiate AERD from ATA
--------------------------------------------------------------------------------------

The serum S1P and urine sphingosine levels were significantly higher in the AERD group than in the ATA group at the basal status, before the ASA-BPT, and at onset of reaction symptoms after the ASA, following the ASA-BPT (*P* \< 0.001 for each, [Fig. 2A](#f2){ref-type="fig"}).

To assess the relationship between the SL metabolites and airway inflammation status, the correlation between the SL metabolites levels at the basal status before the ASA-BPT test and baseline clinical characteristics and biomarkers in asthmatic patients were evaluated ([Table 3](#t3){ref-type="table"}). The levels of serum S1P and urine sphingosine at the basal status before the ASA-BPT test were significantly correlated with a greater decrease in FEV~1~ (%) values during the ASA-BPT (*r* = 0.451, *P* \< 0.001; *r* = 0.553, *P* \< 0.001, respectively, [Fig. 2B](#f2){ref-type="fig"}).

We investigated the correlation with serum periostin, which was known as a novel biomarker of AERD. At the basal status before the ASA-BPT test, the urine sphingosine level was positively correlated with the serum periostin level, however, the serum S1P showed a weak correlation with the basal status of serum periostin (*r* = 0.405, *P* = 0.001; *r* = 0.233, *P* = 0.033 respectively, [Fig. 2C](#f2){ref-type="fig"}).

Using the ROC method, we evaluated the values of the serum S1P and urine sphingosine levels as diagnostic biomarkers for AERD ([Fig. 3](#f3){ref-type="fig"}). To generate the highest levels of sensitivity and specificity, the optimal cut-off values from the ROC curve, a serum S1P \> 93.5 ng/mL and urine sphingosine 33.5 pmol/mg Creatinine (pmol/mg Cr) was chosen. When these values were set, the serum S1P showed 72.2% sensitivity/71.1% specificity (AUC = 0.705, *P* = 0.002) and urine sphingosine showed 77.8% sensitivity/78.9% specificity, (AUC = 0.816, *P* \< 0.001) for discriminating AERD from ATA.

We also examined the correlation between the SL metabolites at the basal status and 15-HETE which has been known to be as a diagnostic biomarker for AERD. The serum 15-HETE level was positively correlated with serum sphingosine (*r* = 0.459, *P* \< 0.001, [Table 3](#t3){ref-type="table"}), while negatively correlated with serum SMs (d18:0/16:0, d18:0/18:0, d18:0/18:1, Lyso SM) (*r* = −0.338, *P* = 0.005; *r* = −0.299, *P* = 0.013, *r* = −0.263, *P* = 0.03; *r* = −0.282, *P* = 0.020 respectively, [Table 3](#t3){ref-type="table"}).

Correlation between the SL metabolites
--------------------------------------

Next, we assessed the correlation between the SL metabolites. The correlation coefficients between the SL metabolites are provided in [Supplementary Tables E1](#S1){ref-type="supplementary-material"} and [E2](#S1){ref-type="supplementary-material"}. At the basal status before the ASA-BPT test, the serum S1P level was positively correlated with urine sphingosine level (*r* = 0.408, *P* \< 0.001, [Fig. 4](#f4){ref-type="fig"}, a1). After the onset of reaction symptoms following ASA-BPT, serum S1P level was correlated weakly with serum sphingosine level (*r* = 0.282, *P* = 0.007, [Fig. 4](#f4){ref-type="fig"}, a2). The level of serum sphingosine at the basal status was negatively correlated with the level of serum SMs (d18:0/16:0, d18:0/18:0, d18:0/18:1, Lyso SM) ([Fig. 4](#f4){ref-type="fig"}, b1--4, Table E1). The serum SM levels were positively correlated with the levels of ceramides (Table E1). The urine SM levels were positively correlated with the levels of urine ceramides (Table E2).

Association of the urine sphingosine level with HLA-DBP1\*0301 and CYSLTR1-634C \> T polymorphism
-------------------------------------------------------------------------------------------------

We examined the association of S1P and sphingosine with *HLA-DBP1\*0301 and CYSLTR1*-634C \> T polymorphism in 89 asthmatic patients comprising of 44 patients with AERD and 45 with ATA (Table E3). In terms of *HLA-DBP1\*0301*, patients with *HLA-DBP\*0301* alleles showed increased urine sphingosine levels at onset of reaction symptoms following the ASA-BPT compared to non-carriers (*P* = 0.012, [Fig. 5a](#f5){ref-type="fig"}). In terms of *CYSLTR1* −634C \> T, patients with either heterozygous CT or homozygous TT genotypes demonstrated higher levels of urine sphingosine at the basal status before the ASA-BPT than those with the homozygous CC genotype (*P* = 0.042, [Fig. 5b](#f5){ref-type="fig"}).

Discussion
==========

AERD is well known as a distinct phenotype and endotype of asthma; it is characterized by eosinophilic inflammation, enhanced leukotriene production and activation of airway mast cells[@b22][@b23]. Recently, novel mechanisms have been proposed, such as systemic inflammation, aberrant functions of platelets and overexpressed platelet activation[@b24][@b25][@b26]. Aspirin challenge, for instance the ASA-BPT, is the gold standard for confirming aspirin hypersensitivity, however, there are still risks for bronchospasm as well as various contraindications[@b27]. In addition, no *in vitro* test has been routinely used for aspirin hypersensitivity despite the fact that AERD patients usually develop severe asthma and a higher frequency of emergency visits, hospitalizations and corticosteroid bursts[@b15][@b16][@b17]. Thus, non-invasive, serological tests should be investigated to determine an ideal biomarker for the AERD phenotype. In this study, we demonstrated the association of SL metabolites in AERD pathogenesis, especially serum S1P and urine sphingosine, could be potential biomarkers for AERD phenotype.

In the present study, we observed the metabolic disturbance of SL in AERD patients. By comparing changes in the SL metabolites following the ASA-BPT, we found a distorted pattern of ceramides and SMs after the ASA-BPT, with a decreased pattern in the AERD group (Fig. E1). In a pairwise comparison before and after the ASA-BPT in the AERD patients, the levels of serum SM (d18:0/18:0, d18:0/18:1, d18:0/24:0, d18:0/24:1) were significantly decreased following the ASA-BPT ([Table 2](#t2){ref-type="table"}, [Fig. 1a](#f1){ref-type="fig"}). Furthermore, serum SM levels showed positive correlations with the concentration of methacholine needed to produce a 20% fall in FEV~1~ from baseline, PC~20~. This indicates that decreased SM levels in AERD patients associated with enhanced airway hyperreactivity. There are several reports supporting the relationship between SL and airway hyperreactivity. Worgall *et al*. demonstrated the association of impaired SL synthesis with airway hyperreacitivity by using *de novo* SPT inhibitor and an SPT knockout mouse model[@b28]. They found that impaired SPT activity induced decreased serum ceramides and sphingosine levels, finally resulting in bronchial hyperreactivity. The direct effect of S1P on airway hyperreactivity has been also reported; S1P administration increased airway reactivity in a dose -- and time-dependent manner in mouse lungs, in which IL-17 may be involved[@b10]. In the present study, we firstly demonstrated the correlation of serum SM levels with methacholine-induced airway hyperreactivity.

The present study demonstrated the potential of serum S1P and urine sphingosine as biomarkers for identifying AERD. Enhanced levels of serum S1P, sphingosine and urine sphingosine were found in patients with AERD compared with those in ATA patients ([Table 2](#t2){ref-type="table"}, [Fig. 2a](#f2){ref-type="fig"}). We also measured the serum S1P level in 29 healthy controls to validate the data and found a significantly increased level of serum S1P in AERD compared to healthy control groups (Fig. E2). In addition, the serum S1P and urine sphingosine levels were significantly correlated with a greater decrease in FEV~1~ (%) values after the ASA-BPT ([Fig. 2b](#f2){ref-type="fig"}). Because the ASA-BPT has been validated and widely used in AERD diagnosis, these results indicate that the serum S1P and urine sphingosine levels are reliable, and safer markers to diagnose the AERD phenotype, without the fear of adverse reactions. We then confirmed the potential of serum S1P and urine sphingosine to differentiate AERD from ATA using ROC analysis, revealing that urine sphingosine is more optimal, with a relatively high sensitivity and specificity ([Fig. 3](#f3){ref-type="fig"}).

Pezato *et al*.[@b24] demonstrated the underlying systemic inflammation of AERD patients. AERD patients showed a differential baseline inflammatory pattern such as an enhanced baseline level of urine leukotriene E4[@b29]. Similarly, the increased levels of S1P and sphingosine in the AERD patients showed positive correlations with the serum 15-HETE level, while the levels of serum SMs were negatively correlated with the serum 15-HETE level ([Table 3](#t3){ref-type="table"}). These findings demonstrate that alteration of SL metabolism (shifting SM into sphingosine and S1P) may be involved in the underlying mechanism of AERD. The SL metabolic pathway is an important cellular pathway that represents a highly coordinated system in which S1P induces cell survival, while ceramide induces programmed cell death[@b2]. According to previous knowledge of SL metabolism, the interconversion of SM into ceramide and S1P is under the control of anabolic and catabolic pathways, in which many kinases and phosphatases are involved, finally determining the cellular value of S1P. Together, S1P and sphingosine may participate in the systemic inflammatory response of AERD.

Next, we investigated the involvement of SLs in various aspects of AERD pathogenesis. Periostin has been suggested as a biomarker for disease severity in asthma as well as the best predictor of airway eosinophilia in asthmatics[@b30]. Periostin is necessary for house-dust mite-induced airway hyperresponsiveness in mice through dendritic cell activation[@b31]. A recent finding has demonstrated that serum periostin could also be used as a biomarker for the AERD phenotype and disease severity[@b21]. In our study, the serum S1P and urine sphingosine levels were positively correlated with the serum periostin level ([Fig. 2c](#f2){ref-type="fig"}). Although the mechanisms of periostin in AERD are not fully understood, it is proposed that exposure to Th2-driven inflammation enhances the overexpression of the *POSTN* gene, resulting an increased level of periostin[@b21]. In addition, IL-13 may induce release of periostin from bronchial epithelial cells[@b32]. S1P is known to be associated with airway hyperactivity and Th2 cytokines in mouse lung[@b10][@b11][@b33]. S1P induction could lead to the release of Th2 cytokines, such as IL-4 and IL-13[@b10][@b34]. Therefore, we speculate that a high level of serum S1P in AERD could generate a Th2 cytokines-rich milieu for the production of periostin, subsequently contributing to more severe airway inflammatory responses.

The suggested genetic mechanisms of AERD are the polymorphisms of genes coding for CYSLTRs and the HLA system. *HLA-DBP1*\*0301 has been proposed as an independent risk factor for the AERD phenotype[@b19]. The frequency of *HLA-DPB1*\*0301 was more prominent in AERD patients than in ATA patients[@b19]. The AERD patients who have *HLA-DBP1*\*0301 showed a higher requirement for leukotriene receptor antagonists for the management[@b35]. In addition, the polymorphism of *CYSLTR1* at position -634 (*C* \> *T*) is associated with the AERD phenotype[@b20]. The frequency of minor alleles of this SNP was higher in male AERD patients than in male ATA patients. Female patients with the *CYSLTR1* -634*CT or TT* genotypes showed an increased total IgE level, perhaps resulting from the elevated production of the Th2 cytokine in this group[@b20]. Similarly, our study revealed that the urine sphingosine levels were increased in *HLA*-DPB1\*0301 carriers and *CYSLTR1* -634 *(C* \> *T)* minor carriers ([Fig. 5](#f5){ref-type="fig"}). The significance seems to be marginal due to limited number of study subjects, thus, further study in a large study cohort is needed to clarify the mechanistic basis regarding how the *HLA*-DPB1\*0301 and *CYSLTR1* gene polymorphisms can influence the level of the urine sphingosine.

Platelets contribute to the pathogenesis of AERD through various pathways, including the formation of platelet-leukocyte aggregates, abnormal function of platelets *in vitro* and overexpression of platelet activation[@b25][@b26][@b36]. After platelet activation, intracellular S1P is released into the environment[@b37][@b38]. *In vitro* studies have found that arachidonic acid could stimulate platelets to secrete S1P through the activation of the thromboxane receptor[@b38]. Recently, integrative pathway-based and conditional Gaussian Bayesian network analyses using multi-omics data have indicated that an altered SL metabolism represents an underlying feature of uncontrolled asthma and a therapeutic response to albuterol[@b39]. Interestingly, the S1P pathway was significantly enriched in the prostaglandin E2 expression signature; thirteen up-regulated and eight down-regulated genes in response to PGE2 treatment were determined to be part of the S1P pathway[@b39]. These findings may suggest a cross-talk between SL and eicosanoid metabolism in the pathogenesis of AERD in which platelet activation and subsequent platelet-leukocyte aggregates might be involved; however, further studies are required to elucidate the relationship between circulating S1P and the underlying systemic inflammation of AERD patients, as well as the downstream effects of S1P in AERD pathogenesis. Understanding the nature of SL metabolism and its pathological effect on the AERD phenotype would be useful in developing novel therapeutic strategies as well as early diagnostic tools.

In conclusion, to our knowledge, this study is the first to demonstrate that S1P and sphingosine are enhanced in AERD patients. SLs may play important roles in AERD pathogenesis. Serum S1P and urine sphingosine may be potential biomarkers for the AERD phenotype.

Materials and Methods
=====================

Study subjects and sample collection
------------------------------------

We recruited 45 AERD and 45 ATA patients from the Ajou University Medical Center (Suwon, Korea) to investigate their SL metabolite profiles. All patients were evaluated for clinical history, chest radiography and pulmonary function tests. Subjects with stable asthma and a baseline FEV~1~ ≥ 50% predicted values underwent methacholine challenge in accordance with American Thoracic Society standards[@b40]. Subjects inhaled aerosolized normal saline, followed by aerosolized saline containing methacholine in doubling doses from 0.03 to 25.0 mg/mL. Methacholine was administered until either FEV~1~ fell by 20% of baseline or until the final dose was administered. If a subject experienced a drop in FEV~1~ from baseline of ≥ 20% before or immediately after the administration of the final dose, the test was considered positive[@b40]. For the ASA-BPT test, the patients were avoided the use of all anti-asthmatic drugs, including leukotriene modifiers, for at least 3 days before. The ASA-BPT was performed with increasing doses of ASA solution (up to 300 mg/mL) using previously described methods, and the tests were defined as positive when FEV~1~% decreased by more than 15% after the challenge[@b41]. The serum and urine samples were collected from the patients at different times; their basal statuses were examined before the ASA-BPT, and their onset of symptoms as well as FEV~1~ were examined after the ASA-BPT. For the ATA patients, the second sampling was performed 4 hours after the last dose of lysine-aspirin. We also recruited 29 normal healthy controls to validate the significant increase of serum S1P at the basal status before the ASA-BPT test ([Supplementary Materials and Methods](#S1){ref-type="supplementary-material"}).

Serum total IgE was measured using the ImmunoCAP system (ThermoFisher Scientific, Uppsala, Sweden), and a range of 2--5000 kU/L. All of the subjects provided written informed consent and the study protocol was approved by the Institutional Review Board of Ajou University Hospital (AJIRB-GEN-SMP-13--108), and all methods were performed in accordance with the relevant guidelines and regulations.

Quantification of SL metabolites
--------------------------------

S1P and sphingosine in both serum and urine samples were quantified using the Mass Hunter Quantitative Analysis B.07.00 system (Agilent Technologies, Santa Clara, CA, USA). D-erythro-Sphingosine C-17 was used as the internal standard for sphingosine and S1P (Cayman Chemical., Ann Arbor, MI, USA). We also used Mass Hunter Quantitative Analysis B.07.00 to quantify the 15-HETE in which the deuterated internal standard 15-HETE-d8 (Cayman Chemical) was used. For the urine samples, creatinine was also quantified to normalize to the actual concentrations of each metabolite and 1,3-dimethyl-2-imidazolidinone (Sigma-Aldrich, St. Louis, MO, USA) was used as the internal standard for creatinine. The concentration of each metabolite was determined from calibration curves using linear regression analysis.

Ceramide and SMs were quantified through a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system equipped with 1290 HPLC (Agilent, Waldbronn, Germany) and QTRAP 5500 (AB Sciex, Toronto, Canada). Multiple reaction monitoring (MRM) was performed in the positive ion mode and the extracted ion chromatogram corresponding to the specific transition for each lipid was used for quantification. The calibration range for each lipid was 0.1--1,000 nM (*r* ≥ 0.99). Data analysis was performed using either Analyst 1.5.2 or Xcalibur software.

The limit of detection was determined as the lowest concentration that can still be detected and distinguished with the limit of blank.

Additional details of the methods used are available in the Methods section of this article's online [supplementary information](#S1){ref-type="supplementary-material"}.

Measurement of serum periostin levels
-------------------------------------

Serum periostin levels were measured with a proprietary sandwich ELISA (Shino-test, Kanagawa, Japan), as previously described[@b21]. ELISA was performed in duplicate. The reported limiting level of periostin for detection using this ELISA system is 100 pg/mL[@b42].

Genotyping
----------

Blood samples were collected from 89 asthmatic patients comprising AERD and ATA before the ASA-BPT test. Genomic DNA was isolated from the peripheral blood using the Puregene DNA purification kit (Gentra, Minneapolis, MN, USA), according to the manufacturer's instructions.

High-resolution typing for *HLA-DBP1\*0301* was performed as previously described, using the amplified gene product of locus specific primers and direct sequencing with the ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA)[@b19]. Genotyping of *CYSLTR1* -634C \> T gene polymorphism (rs321029) was performed as previously described, using a primer extension method with a SNaPshot ddNTP primer extension kit (Applied Biosystems)[@b20].

Statistical analysis
--------------------

We log-transformed the data of methacholine concentration needed to produce a 20% fall in FEV~1~ and the serum total IgE level to correct their skewed distributions. Student's t-test was used to compare continuous outcomes across the levels of each metabolite. General linear regression analysis was performed to adjust for confounding factors, sex and age, to compare the metabolite levels between the AERD and ATA patients. Paired t- test was used to compare paired continuous variables. Spearman's rho correlation analysis identified the associations between continuous variables. To evaluate the diagnostic value of serum S1P and urine sphingosine for identifying AERD, a ROC analysis was used. All *P* values \< 0.05 were considered to be statistically significant. Statistical analyses were performed using SPSS software version 20.0 (IBM Corp., Armonk, NY, USA). GraphPad Prism 5.0 software (GraphPad Inc., San Diego, CA, USA) was used to produce graphs.
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![Changes in serum Sphingomyelin (SM) levels during the ASA-BPT in correlations with methacholine- induced airway hyperreactivity.\
(**a**) Change in serum SM level following the ASA-BPT in the AERD group, (**b**) positive correlations of the serum SM levels at the basal status with PC~20~ to methacholine. Log-transformed data of PC~20~ to methacholine was analyzed.](srep36599-f1){#f1}

![Comparison of the serum S1P and urine sphingosine levels (**a**) between the AERD and ATA groups, data are presented as means ± SD. Correlation of the basal status of serum S1P and urine sphingosine levels with (**b**) the decline of FEV~1~ (%) following the ASA-BPT, and (**c**) serum periostin level.](srep36599-f2){#f2}

![ROC analysis for the basal status of serum S1P and urine sphingosine levels to predict AERD.\
The continuous line represents urine sphingosine and the dashed line represents serum S1P.](srep36599-f3){#f3}

![Correlation between the SL metabolite levels.\
(**a**) Positive correlation of (a1) serum S1P and urine sphingosine at the basal status before the ASA-BPT, (a2) serum S1P and serum sphingosine at onset of reaction symptoms following the ASA-BPT. (**b**) Negative correlation of serum sphingosine level at the basal status with (b1) serum SM (d18:0/16:0), (b2) with serum SM (d18:0/18), (b3) with serum SM (d18:0/18:1), (b4) with serum LysoSM before the ASA-BPT.](srep36599-f4){#f4}

![Association of urine sphingosine level (**a**) at the basal status with *HLA-DBP1*\*0301 and (**b**) at onset of reaction symptoms after the ASA-BPT test with *CYSLTR1*-634C \> T polymorphism.](srep36599-f5){#f5}

###### Clinical demographics of the study subjects.

                                                           AERD                    ATA            *P* value
  ---------------------------------------------- ------------------------ --------------------- -------------
  Age (year)                                      40.27 ± 13.43 (16--69)   46.07 ± 18 (18--74)    **0.045**
  Sex (Female)                                          28 (62.2%)             32 (71.1%)           0.371
  Atopy                                                 26 (57.8%)             17 (38.6%)           0.071
  Total IgE (KU/L)[\*](#t1-fn2){ref-type="fn"}         2.31 ± 0.57             2.06 ± 0.65          0.458
  Baseline FEV~1~ (% Pred)                            84.65 ± 17.94           85.84 ± 16.55         0.79
  \% Fall (FEV~1~)[§](#t1-fn1){ref-type="fn"}         22.57 ± 10.19            4.67 ± 3.56       **\<0.001**
  PC~20~ (mg/mL)[\*](#t1-fn2){ref-type="fn"}           0.25 ± 0.67             0.69 ± 0.55        **0.004**
  Rhinosinusitis                                      39/45 (86.7%)           26/42 (61.9%)       **0.013**
  Nasal polyposis                                     16/45 (37.8%)           7/42 (16.7%)        **0.033**

AERD, aspirin-exacerbated respiratory disease; ATA, aspirin- tolerant asthma; NA, not applicable. The continuous data are presented as the means ± SD. The dichotomous data are presented as numbers (%). The data were analyzed with the t test and Pearson's chi-squared test.

^§^The percent of FEV~1~ decreased during the ASA-BPT. Values in bold indicate significant *P* value.

^\*^Log-transformed data were presented and analyzed with the t test.

###### Sphingolipid composition of patients with AERD and ATA before and after the ASA-BPT.

  Type of sample                       SL metabolites           Before           *P* value[†](#t2-fn2){ref-type="fn"} AERD vs ATA      After      *P* value[†](#t2-fn2){ref-type="fn"} AERD *vs* ATA           AERD                ATA                  
  ----------------------------------- ----------------- ----------------------- -------------------------------------------------- ------------- ---------------------------------------------------- ----------------------- ------------- ----------- -----------
  Serum (ng/mL)                              S1P            101.86 ± 23.48                        85.69 ± 20.76                        0.001                        112.62 ± 20.50                         95.71 ± 16.64       \<**0.001**     0.022     **0.026**
                                         Sphingosine          4.23 ± 6.66                          1.47 ± 1.13                         0.009                         3.24 ± 3.53                            1.58 ± 1.21         **0.004**      0.053       0.286
                                       C16:0 Ceramide        56.48 ± 47.92                        46.02 ± 40.02                        0.391                        41.72 ± 35.71                          39.39 ± 31.36          0.773        0.129       0.347
                                       C18:0 Ceramide       596.9 ± 426.14                       561.39 ± 458.85                       0.753                        459.31 ± 471.8                        698.98 ± 690.07         0.091        0.189       0.258
                                       C18:1 Ceramide        26.16 ± 23.32                        17.89 ± 14.33                        0.096                         19.7 ± 16.23                          21.45 ± 14.5           0.600        0.182       0.284
                                       C20:0 Ceramide       431.63 ± 289.19                      425.25 ± 334.92                       0.856                       401.64 ± 437.73                        528.77 ± 451.32         0.323        0.725       0.236
                                       C24:0 Ceramide     43487.36 ± 68722.91                  46939.51 ± 65163.38                     0.872                     28827.32 ± 31166.87                    45757.38 ± 46134.42       0.111        0.135       0.905
                                       C24:1 Ceramide     16428.46 ± 22695.26                  14179.54 ± 19020.02                     0.469                     13063.48 ± 17229.03                     15799.6 ± 15430.6        0.565        0.225       0.443
                                       SM (d18:0/16:0)   634689.34 ± 834083.29                574655.49 ± 496300.08                    0.478                     418167.27 ± 373508.9                  589256.12 ± 543663.91      0.243        0.050       0.887
                                       SM (d18:0/18:0)   117147.07 ± 100604.79                119072.53 ± 112764.54                    0.758                     87509.14 ± 57956.94                   118776.79 ± 93683.63       0.235      **0.035**     0.990
                                       SM (d18:0/18:1)   288429.15 ± 334236.26                251856.35 ± 230136.98                    0.346                    196502.31 ± 162071.74                  254202.24 ± 186918.08      0.348      **0.038**     0.962
                                       SM (d18:0/24:0)   229334.6 ± 239649.44                 192279.45 ± 160687.77                    0.237                    156231.31 ± 129139.24                  199692.37 ± 163019.24      0.417      **0.028**     0.813
                                       SM (d18:0/24:1)   401790.38 ± 393446.33                300081.46 ± 261921.51                    0.170                    266693.65 ± 207376.38                  318932.87 ± 278792.52      0.469      **0.013**     0.745
                                           Lyso SM         1348.72 ± 1637.08                     1040.93 ± 849.71                      0.239                       908.74 ± 716.62                        1135.74 ± 955.2         0.341        0.060       0.606
  Urine[\*](#t2-fn1){ref-type="fn"}          S1P             34.19 ± 9.86                         34.66 ± 12.43                        0.629                        41.19 ± 1.19 1                        40.32 ± 0.32 6          0.726      **0.001**   **0.005**
  (pmol/mg Cr)                           Sphingosine         48.72 ± 21.58                        31.29 ± 13.66                     \<**0.001**                     50.11 ± 0.11 8                        30.16 ± 0.16 1       \<**0.001**     0.532       0.264
                                       C14:0 Ceramide      154.67 ± 54.67 1                      166.96 ± 66.96 9                      0.596                        144.98 ± 44.98                       242.02 ± 42.02 6         0.355        0.424       0.684
                                       C16:0 Ceramide      2807.85 ± 3699.32                    3304.29 ± 5801.60                      0.446                      2932.36 ± 3180.57                      5292.69 ± 9283.27        0.342        0.335       0.234
                                       C18:0 Ceramide       399.31 ± 38.46                        471.51 ± 86.96                       0.524                        420.10 ± 95.74                        839.06 ± 517.83         0.274        0.437       0.151
                                       C20:0 Ceramide       650.46 ± 16.87                       601.17 ± 305.52                       0.725                        726.95 ± 49.77                        916.92 ± 80.26          0.534        0.275       0.178
                                       C24:0 Ceramide      1861.21 ± 1965.82                    2214.40 ± 3925.29                      0.340                      1962.82 ± 1545.23                      3864.77 ± 7114.12        0.193        0.281       0.137
                                       C24:1 Ceramide       343.32 ± 95.64                       726.78 ± 381.57                       0.058                        378.00 ± 60.49                       1215.88 ± 3931.01        0.250        0.239       0.314
                                         Sphinganine        1184.94 ± 03.38                       464.92 ± 0.14                        0.072                      1255.57 ± 2057.80                      725.73 ± 1036.23         0.214        0.513       0.049
                                       SM (d18:0/16:0)   102343.59 ± 64388.97                  97934.29 ± 92854.80                     0.662                     105220.51 ± 58546.58                  111780.95 ± 85951.83       0.593        0.457       0.144
                                       SM (d18:0/18:0)    24703.85 ± 24562.57                  25473.65 ± 32979.63                     0.259                     23060.26 ± 16354.33                    35243.73 ± 47199.35       0.216        0.900       0.143
                                       SM (d18:0/18:1)     1672.54 ± 1431.48                    2409.25 ± 4176.42                      0.221                      1634.46 ± 1088.91                     4708.95 ± 14959.42        0.248        0.673       0.248
                                       SM (d18:0/24:0)    82282.05 ± 65291.75                  75552.38 ± 69356.22                     0.719                     79694.87 ± 43651.90                    96132.00 ± 80454.76       0.351        0.661       0.074
                                       SM (d18:0/24:1)    40989.74 ± 38049.69                  40254.86 ± 46033.41                     0.450                     38362.31 ± 24894.45                    53031.24 ± 66543.38       0.224        0.863       0.115

AERD, aspirin-exacerbated respiratory disease; ATA, aspirin- tolerant asthma;, SM, sphingomyelin; Cr, creatinine.

^\*^C14 Ceramide and sphinganine were not detected in human serum samples.

^†^*P* value was calculated by GLM, controlling for sex and age. ^¶^Values in bold indicate significant *P* value.

^‡^*P* value was calculated using a paired t-test.

###### Association of baseline levels of serum SL metabolites with clinical features and biomarkers.

                              serum S1P[†](#t3-fn1){ref-type="fn"}   Sphingosine[†](#t3-fn1){ref-type="fn"}   urine S1P[†](#t3-fn1){ref-type="fn"}   Urine Sphingosine[†](#t3-fn1){ref-type="fn"}   SM (d18:0/16:0)[‡](#t3-fn2){ref-type="fn"}   SM (d18:0/18:0)[‡](#t3-fn2){ref-type="fn"}   SM (d18:0/18:1)[‡](#t3-fn2){ref-type="fn"}   SM (d18:0/24:0)[‡](#t3-fn2){ref-type="fn"}   SM (d18:0/24:1)[‡](#t3-fn2){ref-type="fn"}   Lyso SM[‡](#t3-fn2){ref-type="fn"}
  -------------------------- -------------------------------------- ---------------------------------------- -------------------------------------- ---------------------------------------------- -------------------------------------------- -------------------------------------------- -------------------------------------------- -------------------------------------------- -------------------------------------------- ------------------------------------
  PC ~20~ (mg/mL)\*                      −0.214 (0.075)                           −0.230(0.55)                           −0.111 (0.406)                             −0.211 (0.112)                                0.251 (0.051)                                0.236 (0.067)                               0.273\* (0.033)                              0.314\* (0.014)                               0.233 (0.071)                            0.252 (0.050)
  Baseline FEV~1~ (% Pred)               −0.033 (0.794)                          −0.029 (0.818)                          −0.048 (0.732)                             −0.103 (0.460)                                −0.114 (0.422)                               −0.020 (0.890)                               −0.033 (0.818)                               0.023 (0.869)                                0.095 (0.505)                            −0.062 (0.663)
  \% Fall (FEV1)                     0.451\*\*\* (\<0.001)                       0.247 (0.053)                           0.180 (0.207)                          0.553\*\*\* (\<0.001)                             −0.205 (0.152)                               −0.199 (0.166)                               −0.191 (0.183)                               −0.120 (0.406)                               −0.053 (0.716)                           −0.182 (0.205)
  Serum 15-HETE (ng/ml)                  0.152 (0.153)                       0.459\*\*\* (\<0.001)                       −0.124 (0.291)                             0.006 (0.957)                               −0.338\*\* (0.005)                            −0.299\* (0.013)                             −0.263\* (0.030)                              −0.197 (0.108)                               0.001 (0.996)                           −0.282\* (0.020)
  Serum periostin (ng/ml)               0.233\* (0.033)                         0.237\* (0.030)                          −0.102 (0.406)                           0.405\*\* (0.001)                               −0.146 (0.247)                               −0.115 (0.361)                               −0.121 (0.338)                               −0.102 (0.417)                               −0.051 (0.688)                           −0.101 (0.422)

^†^The data presented as Spearman's rho correlation coefficient *r* (*P* value).

^‡^The data presented as Pearson correlation coefficient *r* (*P* value).

[^1]: These authors contributed equally to this work.
